Evidence map›Paper›PMID 42740341›Full record

ArticleJournal of pathology and translational medicine2026

What's new in neoplastic pulmonary pathology 2026: updates on grading, staging and molecular testing.

Andreas Tiefenbacher, Luka Brčić

Abstract read
In one paragraph

Article in Journal of pathology and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Andreas TiefenbacherDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Luka BrčićDepartment of Pathology, Medical University of Vienna, Vienna, Austria. luka.brcic@meduniwien.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoplastic pulmonary pathology has continued to advance in recent years, including the introduction of histologic grading systems for both adenocarcinoma and squamous cell carcinoma, implementation of the UICC TNM 9th Edition classification, expanded molecular testing requirements, refinements in neuroendocrine tumor classification, and improvements in mesothelioma diagnostics. This newsletter summarizes the most important developments relevant to practicing pathologists.

Identifiers

PMID42740341
PMCPMC13586516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.